David Turkaly Analyst PerformanceResearch Analyst at Citizens JmpDavid Turkaly is a stock analyst at Citizens Jmp focused in the medical sector, covering 23 publicly traded companies. Over the past year, David Turkaly has issued 19 stock ratings, including buy and hold recommendations. While full access to David Turkaly's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Turkaly's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings49 Last 10 YearsBuy Recommendations85.71% 42 Buy RatingsCompanies Covered23 Unique Companies Ratings Distribution49RatingsDistribution of strong buy, buy, hold, and sell ratings by David Turkaly.RatingPercentageCount Strong Buy0.0%0 ratings Buy85.7%42 ratings Hold14.3%7 ratings Sell0.0%0 ratingsOut of 49 total stock ratings issued by David Turkaly at Citizens Jmp, the majority (85.7%) have been Buy recommendations, followed by 14.3% Hold.Best & Worst CallsBest Call000.0%SIBNJun 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ICADJan 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ56.5% of companies on NASDAQ13 companiesNYSE43.5% of companies on NYSE10 companiesDavid Turkaly, an analyst at Citizens Jmp, currently covers 23 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical18 companies78.3%Finance3 companies13.0%Computer and Technology2 companies8.7%David Turkaly of Citizens Jmp specializes in stock coverage within the Medical sector, with additional focus on Finance and Computer and Technology companies.Coverage IndustriesIndustryPercentageMED INSTRUMENTS9 companies39.1%MED PRODUCTS5 companies21.7%MED - BIOMED/GENE2 companies8.7%REIT - MTGE TRUST2 companies8.7%MEDICAL INFO SYS1 company4.3%SECURITY1 company4.3%SURGICAL & MEDICAL INSTRUMENTS1 company4.3%COMP - SOFTWARE1 company4.3%REIT - EQTY TRUST - OTHER1 company4.3% About David TurkalyMr. David Turkaly is an Equity Research Analyst at Citizens JMP Securities LLC. He is focused on the medical devices industry. Prior to joining JMP Securites, he served as a Senior Research Analyst at Susquehanna International Group, where he covered medical devices for six years. Mr. Turkaly was previously a Managing Director and Senior Analyst covering the medical devices industry at WR Hambrecht + Co. and a Director and Senior Analyst primarily following the neurological and orthopedic markets at CIBC World Markets Corp. Earlier in his career, he worked in healthcare equity research at ING Barings and in healthcare investment banking at Smith Barney. Mr. Turkaly received his Bachelor of Science in Accounting from University of Richmond and an MBA from Columbia Business School.Follow on LinkedIn David Turkaly's Ratings History at Citizens Jmp Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsLNTHLantheus5/8/2026Boost Price Target$93.99$115.00Market Outperform$0.0000.00% ROIMDXGMiMedx Group4/30/2026Lower Price Target$3.25$6.00Market Outperform$0.0000.00% ROIAXGNAxoGen4/29/2026Boost Price Target$41.77$50.00Market Outperform$0.0000.00% ROIZBHZimmer Biomet4/29/2026Lower Price Target$81.13$105.00Market Outperform$0.0000.00% ROIMDXGMiMedx Group4/20/2026Reiterated Rating$3.41$7.00Market Outperform$0.0000.00% ROITELATELA Bio3/27/2026Lower Price Target$0.72$3.00Market Outperform$0.0000.00% ROILNTHLantheus2/24/2026Boost Price Target$73.18$78.00Market Outperform$0.0000.00% ROIAXGNAxoGen2/24/2026Boost Price Target$32.99$42.00Market Outperform$0.0000.00% ROIMDXGMiMedx Group2/23/2026Initiated Coverage$5.17$10.00Market Outperform$0.0000.00% ROISYKStryker12/19/2025Upgrade$353.03$440.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. TELATELA Bio11/14/2025Lower Price Target$0.95$5.00Market Outperform$0.0000.00% ROIAPYXApyx Medical11/12/2025Upgrade$4.00$8.00Outperform$0.0000.00% ROIAXGNAxoGen10/30/2025Boost Price Target$22.25$34.00Market Outperform$0.0000.00% ROIKIDSOrthoPediatrics10/10/2025Lower Price Target$17.95$25.00Market Outperform$0.0000.00% ROIKIDSOrthoPediatrics8/8/2025Set Price Target$19.20$35.00Market Outperform$0.0000.00% ROILNTHLantheus8/7/2025Lower Price Target$53.79$73.00Market Outperform$0.0000.00% ROIOFIXOrthofix Medical6/6/2025Reiterated Rating$11.02Market Perform$0.0000.00% ROIGMEDGlobus Medical5/27/2025Reiterated Rating$59.00Market Perform$0.0000.00% ROIHAEHaemonetics5/20/2025Reiterated Rating$69.39$100.00Market Outperform$0.0000.00% ROISTESTERIS5/16/2025Boost Price Target$250.35$280.00Market Outperform$0.0000.00% ROIIARTIntegra LifeSciences5/9/2025Lower Price Target$12.63$25.00Market Outperform$00.0000.00% ROIENOVEnovis5/9/2025Lower Price Target$32.52$55.00Market Outperform$00.0000.00% ROIZBHZimmer Biomet5/7/2025Lower Price Target$94.18$125.00Market Outperform$00.0000.00% ROICRWDCrowdStrike5/5/2025Boost Price Target$449.96$500.00Market Outperform$000.0000.00% ROISYKStryker5/5/2025Reiterated Rating$376.27Market Perform$000.0000.00% ROISTESTERIS4/10/2025Reiterated Rating$219.12$265.00Market Outperform$000.0000.00% ROISYKStryker2/18/2025Reiterated Rating$382.74Market Perform$000.0000.00% ROIHAEHaemonetics2/7/2025Lower Price Target$60.90$100.00Market Outperform$00.0000.00% ROILNTHLantheus1/14/2025Reiterated Rating$94.65$112.00Market Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
